Drugs / Bisantrene
Bisantrene
also known as
Bisantrene dihydrochloride · Bisantrene hcl · BISANTRENE HYDROCHLORIDE · Bisantreno · CL 216,942 · NSC-337766 · Orange crush · RC220 · +2 more
Small molecule targets FTO via inhibition
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT06815575 | Apr 2025 → Jul 2027 expected | cancer | Racura Oncology Ltd | Recruiting | No outcome recorded |
| Phase 1 | NCT05456269 | Jul 2022 → Aug 2023 | acute myeloid leukemia, chronic myelomonocytic leukemia, myelodysplastic syndrome | Racura Oncology Ltd | Withdrawn | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT04989335 | Aug 2021 → Dec 2024 | acute myeloid leukemia | Sheba Medical Center | Unknown | No outcome recorded |
| Phase 2 | NCT03820908 | Jul 2019 → May 2020 | acute myeloid leukemia, disease related to hematopoietic stem cell transplant | Sheba Medical Center | Completed | No outcome recorded |
Evidence & citations 15 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Bisantrene | “multiple ascending doses of RC220 bisantrene formulation alone and in combination with fixed dose doxorubicin” NCT06815575 ↗ |
| Known as | Bisantrene dihydrochloride | ChEMBL registry synonym — accepted as the source's own label CHEMBL25336 ↗ |
| Known as | Bisantrene hcl | ChEMBL registry synonym — accepted as the source's own label CHEMBL25336 ↗ |
| Known as | BISANTRENE HYDROCHLORIDE | ChEMBL registry synonym — accepted as the source's own label CHEMBL25336 ↗ |
| Known as | Bisantreno | ChEMBL registry synonym — accepted as the source's own label CHEMBL25336 ↗ |
| Known as | CL 216,942 | ChEMBL registry synonym — accepted as the source's own label CHEMBL25336 ↗ |
| Known as | NSC-337766 | ChEMBL registry synonym — accepted as the source's own label CHEMBL25336 ↗ |
| Known as | Orange crush | ChEMBL registry synonym — accepted as the source's own label CHEMBL25336 ↗ |
| Known as | RC220 | “multiple ascending doses of RC220 bisantrene formulation alone and in combination with fixed dose doxorubicin” NCT06815575 ↗ |
| Known as | Xantrene | “Study of Xantrene® (Bisantrene) in combination with Fludarabine and Clofarabine as Salvage Therapy for Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML)” NCT04989335 ↗ |
| Known as | Zantrene | ChEMBL registry synonym — accepted as the source's own label CHEMBL25336 ↗ |
| Action | Inhibit | “Alpha-ketoglutarate-dependent dioxygenase FTO inhibitor” CHEMBL25336 ↗ |
| Modality | Small molecule | — CHEMBL25336 ↗ |
| Route | Intravenous | “high dose intravenous (IV) bisantrene” NCT05456269 ↗ |
| Target | FTO | “Alpha-ketoglutarate-dependent dioxygenase FTO inhibitor” CHEMBL25336 ↗ |